|
(R)-4-(3-morpholin-4-yl-1-phenylsulfanylmethyl-propylamino)-N-(4-{4-[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-enylmethyl]-piperazin-1-yl}-benzoyl)-3-trifluoromethanesulfonylbenzenesulfonamide bis-hydrochloride |
|---|---|
| Trade Name | |
| Orphan Indication | Multiple myeloma |
| USA Market Approval | USA |
| USA Designation Date | 2008-05-05 00:00:00 |
| Sponsor | AbbVie, Inc.;1 N Waukegan Road, AP34/RA72;North Chicago, Illinois, 60064 |
Related Access Program
AbbVie – Multiple Myeloma
Janssen Research & Development, LLC – Multiple Myeloma
Dana-Farber Cancer Institute – Multiple Myeloma
Bristol-Myers Squibb – Multiple Myeloma
Peking University – Multiple Myeloma
Novartis Pharmaceuticals – Multiple Myeloma
Onyx Pharmaceuticals, Inc., an Amgen subsidiary – Multiple myeloma
